{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:15:19Z","timestamp":1791461719121,"version":"4.3.4"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":2328,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The study aims to systematically assess the diagnostic performance of cardiac magnetic resonance (CMR) and nuclear scintigraphy (index tests) for the diagnosis and differentiation of subtypes of cardiac amyloidosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>MEDLINE and Embase electronic databases were searched for studies evaluating the diagnostic performance of CMR or nuclear scintigraphy in detecting cardiac amyloidosis and subsequently in differentiating transthyretin amyloidosis (ATTR) from immunoglobulin light-chain (AL) amyloidosis. In this meta-analysis, histopathological examination of tissue from endomyocardial biopsy (EMB) or extra-cardiac organs were reference standards. Pooled sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio were calculated, and a random effects meta-analysis was used to estimate diagnostic odds ratios. Methodological quality was assessed using a validated instrument. Of the 2947 studies identified, 27 met the criteria for inclusion. Sensitivity and specificity of CMR in diagnosing cardiac amyloidosis was 85.7% and 92.0% against EMB reference and 78.9% and 93.9% with any organ histology reference. Corresponding sensitivity and specificity of nuclear scintigraphy was 88.4% and 87.2% against EMB reference and 82.0% and 98.8% with histology from any organ. CMR was unable to reliably differentiate ATTR from AL amyloidosis (sensitivity 28.1\u201399.0% and specificity 11.0\u201360.0%). Sensitivity and specificity of nuclear scintigraphy in the differentiation of ATTR from AL amyloidosis ranged from 90.9% to 91.5% and from 88.6% to 97.1%. Pooled negative likelihood ratio and positive likelihood ratio for scintigraphy in this setting were 0.1 and 8, with EMB reference standard. Study quality assessed by QUADAS-2 was generally poor with evidence of bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cardiac magnetic resonance is a useful test for diagnosing cardiac amyloidosis but is not reliable in further classifying the disease. Nuclear scintigraphy offers strong diagnostic performance in both the detection of cardiac amyloidosis and differentiating ATTR from AL amyloidosis. Our findings support the use of both imaging modalities in a non-invasive diagnostic algorithm that also tests for the presence of monoclonal protein.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12511","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T09:12:05Z","timestamp":1567674725000},"page":"1041-1051","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Diagnostic Performance of Imaging Investigations in Detecting and Differentiating Cardiac Amyloidosis: A Systematic Review and Meta-Analysis"],"prefix":"10.1093","volume":"6","author":[{"given":"Jack","family":"Brownrigg","sequence":"first","affiliation":[{"name":"Pfizer Limited , Walton Oaks, Dorking Road, Walton-on-the-Hill, Tadworth, Surrey, KT20 7NS ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Lorenzini","sequence":"additional","affiliation":[{"name":"Barts Heart Centre, St Bartholomew's Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lumley","sequence":"additional","affiliation":[{"name":"Pfizer Limited , Walton Oaks, Dorking Road, Walton-on-the-Hill, Tadworth, Surrey, KT20 7NS ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Elliott","sequence":"additional","affiliation":[{"name":"Barts Heart Centre, St Bartholomew's Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"2026012115090250400_ehf212511-bib-0001","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/eurheartj\/ehv328","article-title":"Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction","volume":"36","author":"Casta\u00f1o","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012115090250400_ehf212511-bib-0002","first-page":"2404","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Clin Perpect Circ"},{"key":"2026012115090250400_ehf212511-bib-0003","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012115090250400_ehf212511-bib-0004","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012115090250400_ehf212511-bib-0005","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness","volume":"37","author":"Damy","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012115090250400_ehf212511-bib-0006","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"2026012115090250400_ehf212511-bib-0007","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM199709253371306","article-title":"The systemic amyloidoses","volume":"337","author":"Falk","year":"1997","journal-title":"N Engl J Med"},{"key":"2026012115090250400_ehf212511-bib-0008","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/qjmed\/91.2.141","article-title":"The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement","volume":"91","author":"Dubrey","year":"1998","journal-title":"QJM"},{"key":"2026012115090250400_ehf212511-bib-0009","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N Engl J Med"},{"key":"2026012115090250400_ehf212511-bib-0010","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"2026012115090250400_ehf212511-bib-0011","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2026012115090250400_ehf212511-bib-0012","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003352","article-title":"Afro-Caribbean heart failure in the United Kingdom: cause, outcomes, and ATTR V122I cardiac amyloidosis","volume":"9","author":"Dungu","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026012115090250400_ehf212511-bib-0013","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012115090250400_ehf212511-bib-0014","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012115090250400_ehf212511-bib-0015"},{"key":"2026012115090250400_ehf212511-bib-0016","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz298","article-title":"Treatment of cardiac transthyretin amyloidosis: an update","author":"Emdin","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012115090250400_ehf212511-bib-0017","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012115090250400_ehf212511-bib-0018","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/eurheartj\/ehs397","article-title":"Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Rapezzi","year":"2012","journal-title":"Eur Heart J"},{"key":"2026012115090250400_ehf212511-bib-0019","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","article-title":"Cardiovascular magnetic resonance in cardiac amyloidosis","volume":"111","author":"Maceira","year":"2005","journal-title":"Circulation"},{"key":"2026012115090250400_ehf212511-bib-0020","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00259-018-4013-4","article-title":"Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis","volume":"45","author":"Treglia","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026012115090250400_ehf212511-bib-0021","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12872-016-0311-6","article-title":"Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis","volume":"16","author":"Zhao","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"2026012115090250400_ehf212511-bib-0022","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jcmg.2016.01.036","article-title":"Prognostic value of late gadolinium enhancement CMR in systemic amyloidosis","volume":"9","author":"Raina","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012115090250400_ehf212511-bib-0023","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"2026012115090250400_ehf212511-bib-0024","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-3-25","article-title":"The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews","volume":"3","author":"Whiting","year":"2003","journal-title":"BMC Med Res Methodol"},{"key":"2026012115090250400_ehf212511-bib-0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2026012115090250400_ehf212511-bib-0026","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jama.1994.03510330081039","article-title":"Users' guides to the medical literature: III. How to use an article about a diagnostic test B. What are the results and will they help me in caring for my patients?","volume":"271","author":"Jaeschke","year":"1994","journal-title":"JAMA"},{"key":"2026012115090250400_ehf212511-bib-0027","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bmj.323.7305.157","article-title":"Systematic reviews of evaluations of diagnostic and screening tests","volume":"323","author":"Deeks","year":"2001","journal-title":"BMJ"},{"key":"2026012115090250400_ehf212511-bib-0028","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa013354","article-title":"Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis","volume":"346","author":"Lachmann","year":"2002","journal-title":"N Engl J Med"},{"key":"2026012115090250400_ehf212511-bib-0029","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3, 3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026012115090250400_ehf212511-bib-0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2026012115090250400_ehf212511-bib-0031","first-page":"116","article-title":"Analysing and presenting results","volume":"4","author":"Deeks","year":"2006","journal-title":"Cochrane handbook Syst Rev Interv"},{"key":"2026012115090250400_ehf212511-bib-0032","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jcmg.2012.04.006","article-title":"Quantification of extracellular matrix expansion by CMR in infiltrative heart disease","volume":"5","author":"Mongeon","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012115090250400_ehf212511-bib-0033","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jcmg.2013.09.019","article-title":"CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis","volume":"7","author":"White","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012115090250400_ehf212511-bib-0034","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jacc.2007.10.049","article-title":"Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy","volume":"51","author":"Vogelsberg","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026012115090250400_ehf212511-bib-0035","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jcmg.2009.08.008","article-title":"Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis","volume":"2","author":"Austin","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012115090250400_ehf212511-bib-0036","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.amjcard.2015.05.021","article-title":"Characterization of cardiac amyloidosis by atrial late gadolinium enhancement using contrast-enhanced cardiac magnetic resonance imaging and correlation with left atrial conduit and contractile function","volume":"116","author":"Kwong","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026012115090250400_ehf212511-bib-0037","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12471-017-1046-4","article-title":"Role of cardiovascular magnetic resonance in suspected cardiac amyloidosis: late gadolinium enhancement pattern as mortality predictor","volume":"26","author":"Baroni","year":"2018","journal-title":"Neth Hear J"},{"key":"2026012115090250400_ehf212511-bib-0038","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.amjcard.2008.09.105","article-title":"Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis","volume":"103","author":"Ruberg","year":"2009","journal-title":"Am J Cardiol"},{"key":"2026012115090250400_ehf212511-bib-0039","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","article-title":"Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis","volume":"6","author":"Karamitsos","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012115090250400_ehf212511-bib-0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12968-017-0376-0","article-title":"Patterns of CMR measured longitudinal strain and its association with late gadolinium enhancement in patients with cardiac amyloidosis and its mimics","volume":"19","author":"Williams","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026012115090250400_ehf212511-bib-0041","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3109\/13506129.2015.1020153","article-title":"Comparison of different types of cardiac amyloidosis by cardiac magnetic resonance imaging","volume":"22","author":"Kristen","year":"2015","journal-title":"Amyloid"},{"key":"2026012115090250400_ehf212511-bib-0042","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcmg.2009.09.023","article-title":"Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis","volume":"3","author":"Syed","year":"2010","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012115090250400_ehf212511-bib-0043","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1253\/circj.CJ-16-0364","article-title":"Left atrial morphology, size and function in patients with transthyretin cardiac amyloidosis and primary hypertrophic cardiomyopathy\u2013comparative strain imaging study","volume":"80","author":"de Gregorio","year":"2016","journal-title":"Circ J"},{"key":"2026012115090250400_ehf212511-bib-0044","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jcmg.2015.05.014","article-title":"Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis","volume":"9","author":"Ternacle","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012115090250400_ehf212511-bib-0045","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026012115090250400_ehf212511-bib-0046","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s10554-018-1385-2","article-title":"Comparison of quantitative imaging parameters using cardiovascular magnetic resonance between cardiac amyloidosis and hypertrophic cardiomyopathy: inversion time scout versus T1 mapping","volume":"34","author":"Da Nam","year":"2018","journal-title":"Int J Cardiovasc Imaging"},{"key":"2026012115090250400_ehf212511-bib-0047","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012115090250400_ehf212511-bib-0048","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/RLI.0b013e318059e021","article-title":"MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis","volume":"42","author":"Hosch","year":"2007","journal-title":"Invest Radiol"},{"key":"2026012115090250400_ehf212511-bib-0049","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/ehjci\/jew101","article-title":"Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis","volume":"17","author":"Bhatti","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012115090250400_ehf212511-bib-0050","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.hlc.2016.12.017","article-title":"The utility of 99mTc-DPD scintigraphy in the diagnosis of cardiac amyloidosis: an Australian experience","volume":"26","author":"Moore","year":"2017","journal-title":"Heart Lung Circ"},{"key":"2026012115090250400_ehf212511-bib-0051","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.rec.2011.12.016","article-title":"Role of cardiac scintigraphy with 99mTc-DPD in the differentiation of cardiac amyloidosis subtype","volume":"65","author":"De Haro-Del Moral","year":"2012","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"},{"key":"2026012115090250400_ehf212511-bib-0052","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s12350-017-0922-z","article-title":"Accuracy of 99mTc-hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis","volume":"26","author":"Cappelli","year":"2017","journal-title":"J Nucl Cardiol"},{"key":"2026012115090250400_ehf212511-bib-0053","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/13506129.2017.1333956","article-title":"Diagnostic score for the detection of cardiac amyloidosis in patients with left ventricular hypertrophy and impact on prognosis","volume":"24","author":"Cariou","year":"2017","journal-title":"Amyloid"},{"key":"2026012115090250400_ehf212511-bib-0054","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcmg.2013.08.015","article-title":"CMR-based differentiation of AL and ATTR cardiac amyloidosis","volume":"7","author":"Dungu","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012115090250400_ehf212511-bib-0055","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1525-1497.2002.10750.x","article-title":"Simplifying likelihood ratios","volume":"17","author":"McGee","year":"2002","journal-title":"J Gen Intern Med"},{"key":"2026012115090250400_ehf212511-bib-0056","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","article-title":"Diagnosis and management of the cardiac amyloidoses","volume":"112","author":"Falk","year":"2005","journal-title":"Circulation"},{"key":"2026012115090250400_ehf212511-bib-0057","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archinte.165.12.1425","article-title":"Senile systemic amyloidosis presenting with heart failure: a comparison with light chain\u2013associated amyloidosis","volume":"165","author":"Ng","year":"2005","journal-title":"Arch Intern Med"},{"key":"2026012115090250400_ehf212511-bib-0058","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"2026012115090250400_ehf212511-bib-0059","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1136\/heartjnl-2014-305710","article-title":"Cardiac magnetic resonance evaluation of left ventricular remodelling distribution in cardiac amyloidosis","volume":"100","author":"Pozo","year":"2014","journal-title":"Heart"},{"key":"2026012115090250400_ehf212511-bib-0060","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jacc.2003.08.043","article-title":"Noninvasive diagnosis of biopsy-proven cardiac amyloidosis","volume":"43","author":"Rahman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026012115090250400_ehf212511-bib-0061","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.amjcard.2011.03.069","article-title":"Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men","volume":"108","author":"Jacobson","year":"2011","journal-title":"Am J Cardiol"},{"key":"2026012115090250400_ehf212511-bib-0062","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.amjcard.2008.09.102","article-title":"Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography","volume":"103","author":"Sun","year":"2009","journal-title":"Am J Cardiol"},{"key":"2026012115090250400_ehf212511-bib-0063","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.hlc.2011.06.002","article-title":"Left atrial size\u2014another differentiator for cardiac amyloidosis","volume":"20","author":"Fitzgerald","year":"2011","journal-title":"Heart Lung Circ"},{"key":"2026012115090250400_ehf212511-bib-0064","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"Echo parameters for differential diagnosis in cardiac amyloidosis. Clinical perspective: a head-to-head comparison of deformation and nondeformation parameters","volume":"10","author":"Pagourelias","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026012115090250400_ehf212511-bib-0065","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/ehjci\/jeu107","article-title":"Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis","volume":"15","author":"Hutt","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012115090250400_ehf212511-bib-0066","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/dc.10370","article-title":"Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test?","volume":"30","author":"Ansari-Lari","year":"2004","journal-title":"Diagn Cytopathol"},{"key":"2026012115090250400_ehf212511-bib-0067","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.amjcard.2014.02.030","article-title":"Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis","volume":"113","author":"Fine","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026012115090250400_ehf212511-bib-0068","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jcmg.2011.03.016","article-title":"Role of 99mTc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis","volume":"4","author":"Rapezzi","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012115090250400_ehf212511-bib-0069","doi-asserted-by":"crossref","first-page":"885","DOI":"10.7326\/0003-4819-97-6-885","article-title":"Endomyocardial biopsy","volume":"97","author":"Fowles","year":"1982","journal-title":"Ann Intern Med"},{"key":"2026012115090250400_ehf212511-bib-0070","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1161\/CIRCULATIONAHA.13.001414","article-title":"Contribution and risks of left ventricular endomyocardial biopsy in patients with cardiomyopathies: a retrospective study over a 28-year period","volume":"128","author":"Chimenti","year":"2013","journal-title":"Circulation"},{"key":"2026012115090250400_ehf212511-bib-0071","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0735-1097(92)90049-S","article-title":"Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center","volume":"19","author":"Deckers","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"2026012115090250400_ehf212511-bib-0072","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1136\/heartjnl-2017-311382","article-title":"Myocardial biopsy: techniques and indications","volume":"104","author":"Francis","year":"2018","journal-title":"Heart"},{"key":"2026012115090250400_ehf212511-bib-0073","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1161\/01.CIR.0000118493.13323.81","article-title":"Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology","volume":"109","author":"Mahrholdt","year":"2004","journal-title":"Circulation"},{"key":"2026012115090250400_ehf212511-bib-0074","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1161\/CIRCULATIONAHA.109.924167","article-title":"Clinical Perspective","volume":"122","author":"Yilmaz","year":"2010","journal-title":"Circulation"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12511","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.12511","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.12511","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/6\/5\/1041\/66136435\/eschf_6_5_1041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/6\/5\/1041\/66136435\/eschf_6_5_1041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:11:45Z","timestamp":1769026305000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/6\/5\/1041\/8403526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":74,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,9,5]]},"published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12511","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"2019-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}